2-Amino-3-(trifluoromethyl)pyridine | CAS:183610-70-0

We serve 2-Amino-3-(trifluoromethyl)pyridine CAS:183610-70-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Amino-3-(trifluoromethyl)pyridine

Chemical Name:2-Amino-3-(trifluoromethyl)pyridine
CAS.NO:183610-70-0
Synonyms:2-Amino-3-(trifluoromethyl)pyridine
3-(Trifluoromethyl)-2-pyridinamine
3-(trifluoromethyl)pyridin-2-amine
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 203.2±35.0 °C at 760 mmHg
Melting Point 70-72ºC
Molecular Formula C6H5F3N2
Molecular Weight 162.113
Flash Point 76.7±25.9 °C
Vapour Pressure 0.3±0.4 mmHg at 25°C
Index of Refraction 1.479
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2-Amino-3-(trifluoromethyl)pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(trifluoromethyl)pyridin-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(Trifluoromethyl)-2-pyridinamine Use and application,3-(Trifluoromethyl)-2-pyridinamine technical grade,usp/ep/jp grade.


Related News: The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.ethyl (2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate manufacturer The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China.5-(Trifluoromethyl)pyridine-2-carboxylic acid supplier At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.sodium,2-chloro-2,2-difluoroacetate vendor China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.